Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Suncoast Research

Neither a doctor nor a teaching hospital

Research payments

$10,705,179

179 payments

Through program year 2025, Suncoast Research is reported as receiving $10,705,179 in research payments, across 179 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $857,176 12
2024 Research $2,355,019 31
2023 Research $1,409,066 22
2022 Research $1,205,094 20
2021 Research $1,770,015 45
2020 Research $1,621,453 29
2019 Research $1,487,357 20

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $10,510,579 153 payments
  2. Sanofi Pasteur Inc. $185,131 15 payments
  3. Eli Lilly Export S.A. Puerto Rico Branch $8,446 3 payments
  4. Pfizer Inc. $1,023 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3556050 for the Treatment of Osteoarthritis Pain $1,488,235 10 payments
  2. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $1,294,862 4 payments
  3. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $858,777 11 payments
  4. A Study of Tirzepatide (Ly3298176) Once A Week Versus Insulin Glargine Once A Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk $790,041 7 payments
  5. A Study of Ly3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain $753,333 4 payments
  6. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain $523,710 5 payments
  7. Randomized Placebo Controlled Phase 2 Clinical Trial to Evaluate Ly3556050 for the Treatment of Osteoarthritis Pain $498,207 2 payments
  8. A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly As Add-On Therapy to Metformin in Patients With Type 2 Diabetes $386,075 6 payments
  9. A Study of Retatrutide (Ly3437943) in Participants Who Have Obesity Or Overweight (Triumph-1) $371,391 2 payments
  10. A Study of Retatrutide (Ly3437943) Once Weekly in Participants Who Have Obesity Or Overweight and Osteoarthritis of the Knee (Triumph-4) $347,963 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record